Discover 112 paid clinical trials in Charleston, West Virginia. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 112
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
for
Locally Advanced Cervical Adenocarcinoma,
Location: Charleston WV, Parkersburg WV, Roanoke VA,
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT07061977
Phase3, Recruiting
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
for
Down Syndrome, Recurrent B Acute Lymphoblastic Leukemia
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
for
Renal Pelvis and Ureter Urothelial Carcinoma
Location: Charleston WV, Washington PA, Lexington KY,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT04628767
Phase2, Phase3, Recruiting
Project: Every Child for Younger Patients With Cancer
for
Adrenal Gland Pheochromocytoma, Carcinoma In Situ,
Location: Charleston WV, Huntington WV, Roanoke VA, Morgantown WV,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 25
Code: NCT02402244
Recruiting
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
for
Acute Myeloid Leukemia
Location: Charleston WV, Roanoke VA, Columbus OH, Lexington KY,
Sponsor: Children's Oncology Group
Sex: All
Age: 0 - 21
Code: NCT04293562
Phase3, Recruiting
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
for
Metastatic Head and Neck Squamous Cell Carcinoma,
Location: Charleston WV, Uniontown PA, Washington PA,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06589804
Phase3, Recruiting
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer